Compare · CGIX vs CI
CGIX vs CI
Side-by-side comparison of Cancer Genetics, Inc. (CGIX) and The Cigna Group (CI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CGIX and CI operate in Medical Specialities (Health Care), so they compete in similar markets.
- CI carries a market cap of $77.37B.
- CI has hit the wire 14 times in the past 4 weeks while CGIX has been quiet.
- CI has more recent analyst coverage (25 ratings vs 0 for CGIX).
- Company
- Cancer Genetics, Inc.
- The Cigna Group
- Price
- -
- -
- Market cap
- -
- $77.37B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- n/a
- News (4w)
- 0
- 14
- Recent ratings
- 0
- 25
The Cigna Group
Cigna Corporation provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's U.S. Medical segment offers commercial products and services, including medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as Medicaid plans; and individual health insurance plans to on and off the public exchanges. Its International Markets segment offers health coverage, hospitalization, dental, critical illness, personal accident, term life, medical cost containment, and variable universal life products, as well as health care benefits to mobile employees of multinational organizations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
Latest CGIX
- SEC Form 4: John R Fletcher was granted 8,676 units of Common Stock
- SEC Form 4 filed by Marcus Boehm
- SEC Form 4 filed by Joanna Horobin
- SEC Form 4 filed by Howard Mcleod
- SEC Form 4 filed by Yung-Ping Yeh
- SEC Form 4 filed by R. Paul Hansen
- SEC Form 4 filed by E. Geoffrey Harris
- SEC Form 4 filed by Ralf Brandt
- SEC Form 4 filed by D.C. Andrew Lafrence
- SEC Form 4 filed by A John Roberts
Latest CI
- Director Foss Eric J was granted 782 shares, increasing direct ownership by 2% to 36,696 units (SEC Form 4)
- Director Mcclellan Mark B. was granted 782 shares, increasing direct ownership by 13% to 6,891 units (SEC Form 4)
- Director Zarcone Donna F was granted 782 shares, increasing direct ownership by 3% to 27,517 units (SEC Form 4)
- Director Hathi Neesha was granted 782 shares, increasing direct ownership by 23% to 4,151 units (SEC Form 4)
- Director Mazzarella Kathleen M was granted 782 shares, increasing direct ownership by 13% to 6,891 units (SEC Form 4)
- Director Kurian George was granted 782 shares, increasing direct ownership by 21% to 4,560 units (SEC Form 4)
- Director Ross Kimberly A. was granted 782 shares, increasing direct ownership by 17% to 5,294 units (SEC Form 4)
- Director Hennigan Michael J was granted 782 shares, increasing direct ownership by 138% to 1,350 units (SEC Form 4)
- Director Ozuah Philip was granted 782 shares, increasing direct ownership by 43% to 2,583 units (SEC Form 4)
- Director Wiseman Eric C was granted 782 shares, increasing direct ownership by 3% to 23,940 units (SEC Form 4)